PHASE I ORAL CAPECITABINE + CISPLATIN FOR ADVANCED DIGESTIVE SYSTEM CANCERS

该子项目是利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得主要资金， 因此可以在其他CRISP条目中表示。列出的机构是 中心，不一定是研究者的机构。 这是一项在晚期消化系统癌症患者中进行的口服氟嘧啶卡培他滨（希罗达）间歇给药联合静脉顺铂的I期研究。 目的是确定剂量限制性毒性、最大耐受剂量和推荐的II期剂量。 将确定联合药物之间的显著相互作用。 可能的抗肿瘤有效性将被确定为次要目的。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a Phase I study of oral fluoropyrimidine capecitabine (Xeloda) delivered on an intermittent schedule and combined with intravenous cisplatin in patients with advanced cancer of the digestive system. The objectives are to establish dose-limiting toxicities, maximum tolerated dose, and the recommended Phase II dose. Significant interaction between the combined agents will be determined. Possible antitumor effectiveness wil be determined as a secondary objective.